prof. dr. ir. Barbara Vanderstraeten
- ORCID iD
- 0000-0001-7160-5865
Show
Sort by
-
Moderate hypofractionated radiotherapy for prostate cancer : 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial
-
Peripheral blood lymphocytes differ in DNA damage response after exposure to X-rays with different physical properties
-
- Journal Article
- A1
- open access
ARCHERY : a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer : study protocol
-
B-QUATRO clinical audits: A Belgian success story?
-
- Journal Article
- A1
- open access
Impact of proton therapy on the DNA damage induction and repair in hematopoietic stem and progenitor cells
-
The DNA damage response of peripheral blood lymphocytes exposed to X-rays with different physical properties
-
- Conference Paper
- C3
- open access
The DNA damage response of peripheral blood lymphocytes exposed to X-rays with different beam qualities and quantities
-
- Journal Article
- A2
- open access
Dose-volume-based evaluation of convolutional neural network-based auto-segmentation of thoracic organs at risk
-
- Journal Article
- A1
- open access
Handle with care : the anterior hip capsule plays a key role in daily hip performance
-
Prediction of the table position during radiation treatment based on CT images, patient immobilisation and treatment planning parameters
-
Clinical evaluation of deep learning for auto-segmentation of computed tomography (CT) images in radiotherapy for lung cancer
-
Prediction of the table position during radiation treatment based on CT images, patient immobilisation and treatment planning parameters
-
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial
-
- Conference Paper
- C3
- open access
Four- or 5-weeks of radiotherapy for prostate cancer : interim results of a randomized phase 3 trial
-
Automated instead of manual treatment planning? : a plan comparison based on dose-volume statistics and clinical preference